Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Abbott and Wyeth to Develop Test for Sirolimus

By HospiMedica staff writers
Posted on 28 Dec 2003
A collaboration to jointly develop an automated blood test to monitor therapeutic levels of sirolimus, an anti-rejection drug for transplant patients, has been announced by Abbott Laboratories (Abbott Park, IL, USA) and (Madison, NJ, USA). More...


Under the agreement, the two companies will develop the test for use on Abbott's Imx and other automated immunoassay systems. The test will be manufactured by Axis-Shield plc (Dundee, Scotland), and Abbott will distribute it worldwide. Abbott now provides tests to monitor the immunosuppressant drugs cyclosporine and tacrolimus. A lifelong regimen of immunosuppressant drugs is given to transplant patients to lower the body's normal immune response and allow the transplanted organ to remain functional. Sirolimus is recommended for the prophylaxis of organ rejection in patients receiving a renal transplant.

"Our agreement with Wyeth builds upon our leadership position in transplant diagnostics and reinforces our commitment to improve the medical outcome for patients who have undergone kidney transplants,” said William Brown, Ph.D., vice president, diagnostic assays and systems development, Abbott Laboratories.




Related Links:
Abbott
Wyeth

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.